APOBEC3D and breast carcinoma: Our results with APOBEC3D likely indicate a parallel with APOBEC3B in breast cancer, a mutagenic activity of APOBEC3D in CRCs, and suggest survival benefit with a specific inhibitor of APOBEC3D.